Literature DB >> 1971318

Cure of duodenal ulcer associated with eradication of Helicobacter pylori.

E A Rauws1, G N Tytgat.   

Abstract

50 patients with intractable duodenal ulcer were randomly assigned to 4 weeks of treatment with colloidal bismuth subcitrate (CBS) alone (26 patients) or with amoxicillin and metronidazole (24 patients). 5 patients (all on triple therapy) withdrew because of side-effects. In 17 of the 45 patients who completed the treatment, Helicobacter pylori was eradicated, and there was no ulcer relapse during the first 12 months of follow-up. The ulcer relapse rate was significantly higher (17 of 21 [89%]) among patients who remained positive for H pylori. 9 patients who remained positive for H pylori and had ulcer relapses within 6 months of treatment with CBS alone, were subsequently given triple therapy. 7 of the 9 showed H pylori eradication and no relapses within the next 12 months. The 2 patients still H pylori-positive after triple therapy had further ulcer relapses. H pylori eradication, without altering acid output, will become the mainstay of duodenal ulcer treatment because it cures the disease.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1971318     DOI: 10.1016/0140-6736(90)91301-p

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  219 in total

1.  Does treatment of Helicobacter pylori with antibiotics alone heal duodenal ulcer? A randomised double blind placebo controlled study.

Authors:  S K Lam; C K Ching; K C Lai; B C Wong; C L Lai; C K Chan; L Ong
Journal:  Gut       Date:  1997-07       Impact factor: 23.059

2.  In vitro anti-Helicobacter pylori activities of new rifamycin derivatives, KRM-1648 and KRM-1657.

Authors:  J K Akada; M Shirai; K Fujii; K Okita; T Nakazawa
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

Review 3.  Role of Helicobacter pylori in duodenal ulcer.

Authors:  E A Rauws
Journal:  Drugs       Date:  1992-12       Impact factor: 9.546

4.  Helicobacter pylori and peptic ulcer recurrence.

Authors:  M Guslandi
Journal:  Gut       Date:  1992-09       Impact factor: 23.059

5.  In vitro susceptibilities of Actinobacillus actinomycetemcomitans to a number of antimicrobial combinations.

Authors:  M J Pavicić; A J van Winkelhoff; J de Graaff
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

6.  Duodenal ulcer disease: to treat H. pylori infection or not?

Authors:  J B Marshall
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

7.  Helicobacter pylori--our knowledge is growing.

Authors:  D G Colin-Jones
Journal:  Postgrad Med J       Date:  1990-10       Impact factor: 2.401

8.  RELATIONSHIP BETWEEN THE PRESENCE OF HELICOBACTER PYLORI WITH INFLAMMATORY ENDOSCOPIC CHANGES IN GASTRODUODENAL MUCOSA.

Authors:  Irma Cláudia Saboya Ribeiro; Luiz Fernandao Kubrusly; Paulo Afonso Nunes Nassif; Patrícia Fernanda Saboya Ribeiro; Rodrigo de Oliveira Veras; Aline Neppel
Journal:  Arq Bras Cir Dig       Date:  2016 Jul-Sep

9.  Do we eradicate Helicobacter pylori in hospitalized patients with peptic ulcer disease?

Authors:  Frank Wong; George Ou; Sigrid Svarta; Ricky Kwok; Kieran Donaldson; Joe Frenette; Robert Enns
Journal:  Can J Gastroenterol       Date:  2013-09-13       Impact factor: 3.522

10.  Omeprazole-amoxycillin therapy for eradication of Helicobacter pylori in duodenal ulcer bleeding: preliminary results of a pilot study.

Authors:  D Jaspersen; T Körner; W Schorr; M Brennenstuhl; C H Hammar
Journal:  J Gastroenterol       Date:  1995-06       Impact factor: 7.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.